121 related articles for article (PubMed ID: 38877529)
21. BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1-driven Immune Phenotypes with Distinct Spatial Orchestration.
Bady E; Möller K; Mandelkow T; Raedler JB; Yang C; Ebner J; Lurati MCJ; Simon R; Vettorazzi E; Büscheck F; Luebke AM; Dum D; Menz A; Sauter G; Höflmayer D; Weidemann S; Fraune C; Uhlig R; Bernreuther C; Jacobsen F; Clauditz TS; Wilczak W; Burandt E; Steurer S; Minner S; Lennartz M; Blessin NC
Mol Cancer Res; 2023 Jun; 21(6):605-613. PubMed ID: 36976297
[TBL] [Abstract][Full Text] [Related]
22. Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer.
Tashireva LA; Kalinchuk AY; Gerashchenko TS; Menyailo M; Khozyainova A; Denisov EV; Perelmuter VM
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674951
[TBL] [Abstract][Full Text] [Related]
23. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.
Beckinger S; Daunke T; Aldag L; Krüger S; Heckl S; Wesch D; Schäfer H; Röcken C; Rahn S; Sebens S
Front Oncol; 2023; 13():1160824. PubMed ID: 37207152
[TBL] [Abstract][Full Text] [Related]
24. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
[TBL] [Abstract][Full Text] [Related]
25. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.
Taube JM; Roman K; Engle EL; Wang C; Ballesteros-Merino C; Jensen SM; McGuire J; Jiang M; Coltharp C; Remeniuk B; Wistuba I; Locke D; Parra ER; Fox BA; Rimm DL; Hoyt C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266881
[TBL] [Abstract][Full Text] [Related]
26. The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer.
Yang L; Zhang W; Sun J; Yang G; Cai S; Sun F; Xing L; Sun X
Cancer Immunol Immunother; 2023 Jul; 72(7):2015-2027. PubMed ID: 36738309
[TBL] [Abstract][Full Text] [Related]
27. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
28. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
[TBL] [Abstract][Full Text] [Related]
29. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
30. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K; Zygoura P; Norkin M; Tissot S; Shakarishvili N; Popat S; Curioni-Fontecedro A; O'Brien M; Pope A; Shah R; Fisher P; Spicer J; Roy A; Gilligan D; Rusakiewicz S; Fortis E; Marti N; Kammler R; Finn SP; Coukos G; Dafni U; Peters S; Stahel RA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880184
[TBL] [Abstract][Full Text] [Related]
31. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
32. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images.
Surace M; Rognoni L; Rodriguez-Canales J; Steele KE
Methods Enzymol; 2020; 635():33-50. PubMed ID: 32122552
[TBL] [Abstract][Full Text] [Related]
34. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
35. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
36. Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma.
Yaseen Z; Gide TN; Conway JW; Potter AJ; Quek C; Hong AM; Long GV; Scolyer RA; Wilmott JS
Front Mol Biosci; 2022; 9():810858. PubMed ID: 35664673
[TBL] [Abstract][Full Text] [Related]
37. Antitumor immune response is associated with favorable survival in GEP-NEN G3.
Rosery V; Reis H; Savvatakis K; Kowall B; Stuschke M; Paul A; Dechêne A; Yang J; Zhao B; Borgers A; Kasper S; Schuler M; Cheung PF; Siveke JT
Endocr Relat Cancer; 2021 Sep; 28(10):683-693. PubMed ID: 34472429
[TBL] [Abstract][Full Text] [Related]
38. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer.
Wu J; Sun W; Yang X; Wang H; Liu X; Chi K; Zhou L; Huang X; Mao L; Zhao S; Ding T; Meng B; Lin D
Mod Pathol; 2022 Feb; 35(2):218-227. PubMed ID: 34493824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
